Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.62%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.53%AUDUSD-1.44%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.81%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.68%CADJPY-0.66%NZDJPY-0.65%USDCHF+0.63%GBPUSD-0.62%USDCAD+0.58%EURUSD-0.58%NZDUSD-0.54%AUDSGD-0.51%AUDDKK-0.43%USDZAR+0.42%GBPTRY+0.41%NZDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%USDMXN+0.31%GBPMXN-0.28%EURZAR+0.28%USDNOK+0.26%GBPZAR+0.25%USDTRY+0.21%USDSEK+0.20%USDPLN+0.19%CHFNOK+0.18%EURCNH-0.17%USDILS+0.16%NOKJPY-0.15%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.12%USDCNH-0.12%USDJPY-0.11%EURNOK+0.10%GBPSGD-0.10%EURSGD-0.08%GBPNZD-0.07%PLNJPY-0.07%EURSEK+0.06%SGDJPY+0.06%USDSGD+0.06%GBPCAD-0.06%NZDCHF+0.05%EURGBP+0.05%EURPLN+0.05%EURCHF+0.05%USDCOP-0.04%CADCHF+0.04%EURNZD-0.04%EURCZK+0.04%CHFSGD-0.02%NZDCAD+0.01%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.75%XPTUSD-0.73%W1-0.51%C1-0.41%XAUUSD-0.30%GAUUSD-0.29%HG1-0.23%GAGUSD-0.22%UKOIL+0.21%XAGUSD-0.21%S1-0.17%COTTON+0.10%BTCUSD-2.91%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-5.93%XMRUSDT-1.68%DOGEUSD+55.95%LINKUSD-2.70%XLMUSD-3.12%BCHUSDT-3.08%LTCUSD+47.50%UNIUSD-2.23%SUIUSD-2.16%TONUSD+59.18%HBARUSDT-4.75%TAOUSDT-2.34%AAVEUSD-2.66%ONDOUSDT-4.17%ICPUSDT-1.39%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.23%ATOMUSDT-1.79%INJUSDT-6.62%STXUSDT-1.86%PYTHUSDT+0.43%TIAUSDT-2.26%FETUSDT-3.90%JUPUSDT+1.01%SEIUSDT-2.00%GRTUSDT-2.83%OPUSDT-2.63%IOTAUSDT-1.99%POLUSDT-1.48%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-5.97%GALAUSDT-1.65%DYDXUSDT-2.23%ORDIUSDT-1.75%NOTUSDT-0.74%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.62%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.53%AUDUSD-1.44%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.81%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.68%CADJPY-0.66%NZDJPY-0.65%USDCHF+0.63%GBPUSD-0.62%USDCAD+0.58%EURUSD-0.58%NZDUSD-0.54%AUDSGD-0.51%AUDDKK-0.43%USDZAR+0.42%GBPTRY+0.41%NZDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%USDMXN+0.31%GBPMXN-0.28%EURZAR+0.28%USDNOK+0.26%GBPZAR+0.25%USDTRY+0.21%USDSEK+0.20%USDPLN+0.19%CHFNOK+0.18%EURCNH-0.17%USDILS+0.16%NOKJPY-0.15%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.12%USDCNH-0.12%USDJPY-0.11%EURNOK+0.10%GBPSGD-0.10%EURSGD-0.08%GBPNZD-0.07%PLNJPY-0.07%EURSEK+0.06%SGDJPY+0.06%USDSGD+0.06%GBPCAD-0.06%NZDCHF+0.05%EURGBP+0.05%EURPLN+0.05%EURCHF+0.05%USDCOP-0.04%CADCHF+0.04%EURNZD-0.04%EURCZK+0.04%CHFSGD-0.02%NZDCAD+0.01%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.75%XPTUSD-0.73%W1-0.51%C1-0.41%XAUUSD-0.30%GAUUSD-0.29%HG1-0.23%GAGUSD-0.22%UKOIL+0.21%XAGUSD-0.21%S1-0.17%COTTON+0.10%BTCUSD-2.91%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-5.93%XMRUSDT-1.68%DOGEUSD+55.95%LINKUSD-2.70%XLMUSD-3.12%BCHUSDT-3.08%LTCUSD+47.50%UNIUSD-2.23%SUIUSD-2.16%TONUSD+59.18%HBARUSDT-4.75%TAOUSDT-2.34%AAVEUSD-2.66%ONDOUSDT-4.17%ICPUSDT-1.39%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.23%ATOMUSDT-1.79%INJUSDT-6.62%STXUSDT-1.86%PYTHUSDT+0.43%TIAUSDT-2.26%FETUSDT-3.90%JUPUSDT+1.01%SEIUSDT-2.00%GRTUSDT-2.83%OPUSDT-2.63%IOTAUSDT-1.99%POLUSDT-1.48%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-5.97%GALAUSDT-1.65%DYDXUSDT-2.23%ORDIUSDT-1.75%NOTUSDT-0.74%RONINUSDT-2.92%
IM

ImmunityBio, Inc. (IBRX)

NASDAQ • Healthcare

$6.7
+$0.44 (+7.0%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$6.26
Day Range$6.12 - $6.78
Avg. Volume (3M)13M
Market Cap$7.1B
52 Week Range
$1.95$12.43

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$48.8M100%
Gross Profitminus cost of goods$47.5M97%

Fundamentals & Financials

Revenue (TTM)
$182.5M
Net Income (TTM)
-$1.1B
EPS (TTM)
-$1.07
ROA (TTM)
-182.09%
Current Ratio
4.27
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-675.0%Q2 2026-$0.62
-175.0%Q3 2026-$0.22
-142.9%Q4 2026-$0.17

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -142.9%

ImmunityBio’s third fiscal quarter of 2026 results missed consensus on both revenue and adjusted EPS, as reported November 9, 2026, even as sales grew sharply year over year. Revenue rose 52.3% to roughly $48.8 million (up from about $32.1 million a year ago) but trailed expectations, coming in at $48.8 million versus a $59.2 million estimate (-17.5%). Adjusted EPS of -$0.17 also trailed the -$0.07 estimate by -$0.10 and was down from -$0.07 a year ago. Profitability remained pressured despite a gross margin of about 97%, with gross profit of roughly $47.5 million alongside an operating loss of about $78.0 million, translating to an operating margin near -160%. Net income was a loss of roughly $184.6 million, compared with a loss of about $67.3 million a year ago (-174.4%). For the next period, consensus calls for EPS of -$0.10 on revenue of $62.5 million.

View full earnings history

About ImmunityBio, Inc.

ImmunityBio, Inc. (NASDAQ: IBRX) is a biotechnology company that develops therapies and vaccines for cancer and infectious disease using immunotherapy and cell therapy platforms. In FY2025, it generated $113.3 million in revenue. Its programs span antibody-cytokine fusion proteins, immunomodulators, vaccine technologies, NK cell therapies, and T-cell strategies.

Name
ImmunityBio, Inc.
CEO
Richard Gerald Adcock
Industry
Healthcare
Year Founded
2014
Employees
688

Today's Snapshot

AI-generated

IBRX closed 7% higher at 6.70, outperforming a weaker sector.

Trading Volume

Below 10d avg (17.2M)

15.6M

vs S&P 500 Today

Strong Outperformance

+7.29%

Updated: November 18, 2026 at 21:09 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
IBRX shows a clear bearish bias as price sits below its short, medium and long moving averages while momentum indicators and MACD are negative, signaling selling pressure. ADX around the mid-20s points to a meaningful trend rather than chop, and on-balance volume reads as weak, suggesting distribution rather than accumulation. Volatility is notable relative to price with an ATR near the mid-single-digit cents, which can amplify downside moves. The classic pivot sits below the current price but does not offset the weight of bearish averages and momentum. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$6.81 - $8.03
    Sell
  • RSI (14)40.71
    Neutral
  • Stochastic %K (14, 3, 3)17.35
    Buy
  • MACD Level (12, 26)-0.70
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.